As reported here, earlier this month the U.S. Drug Enforcement Administration (DEA) issued a decision declining to transfer marijuana out of Schedule I. As marijuana remains a Schedule I...07 September 2016
Webinar | FDA's Regulation of Stem Cells and Regenerative Medicine in Light of Regenerative Sciences
- Can stem cell therapies still be considered within the practice of medicine and outside the realm of FDA oversight?
- The implications of Regenerative Sciences with respect to pre- and post-market oversight.
- The effect of growing demand for stem cell treatments and the risks of medical tourism to countries with inadequate regulatory oversight.
- Development models: practical pathways from research to profitability.
The webinar will feature moderator Michael Druckman and speakers Michael Levinson, M.D., J.D. Randy Prebula, and the founder and executive director of the Genetics Policy Institute Bernard Siegel, who is also the founder and co-chair of the World Stem Cell Summit.
Update: Listen to the webinar here.